Nintedanib(OFEV)

A prescription drug targeting tyrosine kinases such as PDGFR-α/β, FGFR1-3, VEGFR1-3, CSF1R and FLT-3. It was approved in the United States in October 2014 for the treatment of idiopathic pulmonary fibrosis (IPF) and must be used strictly in accordance with medical advice.

Targets of Action

Tyrosine kinases including PDGFR-α/β, FGFR1-3, VEGFR1-3, CSF1R and FLT-3.

Mechanism of Action

Nintedanib is a multi-targeted tyrosine kinase inhibitor (TKI) that exerts its effect by inhibiting the signaling pathways associated with the pathogenesis of interstitial lung diseases (ILDs).

Dosage and Administration

Route and frequency of administration for Nintedanib: 150 mg, oral administration, twice daily.

The dosage of Nintedanib needs to be adjusted according to the patient's actual condition; for specific circumstances, patients should consult a doctor and follow the medical advice strictly.

Recommended reading: Dosage and Administration of Nintedanib

Adverse Reactions

Key Risks and Warnings: Hepatic impairment, gastrointestinal disorders, embryo-fetal toxicity, etc.

Common Adverse Reactions: Diarrhea, nausea, abdominal pain, elevated liver enzymes.

Reference article: Adverse Reactions of Nintedanib

Use in Special Populations

Pregnancy: Nintedanib can cause fetal harm (embryo-fetal death, structural abnormalities). Use in pregnant women may pose risks to the fetus, and potential hazards must be informed to patients.

Lactation: As Nintedanib may cause serious adverse reactions in breastfed infants, women are advised to avoid breastfeeding during treatment.

General Precautions

1. It is of vital importance to read the patient medication information provided by the manufacturer before initiating Nintedanib treatment and at each prescription refill.

2. Nintedanib must be taken with food, which is particularly important. The capsules should be swallowed whole with liquid, and must not be chewed or crushed; strict compliance is required during administration. If the capsule contents are accidentally contacted, hands should be washed immediately.

3. If a dose of Nintedanib is missed, do not make up the missed dose; skip the missed dose and take the next regular dose at the scheduled time. Do not double the dose to compensate for the missed one.

FDA，2024.10